171 results
424B3
BXRXQ
Baudax Bio, Inc.
22 Nov 23
Prospectus supplement
4:58pm
effective tax rate due to changes in the mix of earnings in countries with differing statutory tax rates, changes in the valuation of deferred tax assets … and liabilities, tax impacts and net operating loss utilization related to the separation from Societal CDMO’s acute care business and transfer
8-K
EX-99.1
BXRXQ
Baudax Bio, Inc.
29 Sep 23
Baudax Bio Announces Orphan Drug Designation Granted by U.S. FDA for TI-168 for the Treatment of Hemophilia A with Inhibitors
7:01am
the potential for market exclusivity for seven years upon FDA approval, eligibility for tax credits for qualified clinical trials, waiver of application fees
PRER14A
agixjh0j xue4ek
25 Aug 23
Preliminary revised proxy
4:01pm
8-K
EX-10.1
v8y9l vkgba6
25 Aug 23
Entry into a Material Definitive Agreement
8:03am
DEFA14A
kzvl37rptpcd pvj
21 Aug 23
Additional proxy soliciting materials
8:05am
8-K
EX-4.2
ahpyrrch 8kix
21 Aug 23
Entry into a Material Definitive Agreement
8:00am
8-K
EX-10.1
s70qkciv
21 Aug 23
Entry into a Material Definitive Agreement
8:00am
8-K
EX-4.1
mqb0gdcav12vx5sbzoot
21 Aug 23
Entry into a Material Definitive Agreement
8:00am
424B5
a9ngyeyq8k 4t5hsw
18 Aug 23
Prospectus supplement for primary offering
4:40pm
8-K
EX-99.1
kx8tgjuthafg1v23g
16 Aug 23
Baudax Bio Reports Second Quarter 2023 Financial Results and Provides Business Update
8:11am